Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

NCT04816214 · GEOMETRY-E Phase 3Terminated

Lead sponsor: Novartis Pharmaceuticals (Industry)
Enrollment: 6 (actual)
Start date: 22 Sep 2021
Primary completion: 27 Dec 2022 (actual)
Study completion: 27 Dec 2022
Last update posted: 5 Mar 2024

Design

Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel
Masking: None
Arms: 3

Interventions

Capmatinib Drug
Osimertinib Drug
Pemetrexed Drug
Cisplatin Drug
Carboplatin Drug

Conditions and primary outcome

Carcinoma, Non-Small-Cell Lung

Primary outcome

Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) (Up to 21 Days); Randomized Part: Progression Free Survival (PFS) Based on BIRC Assessment (From randomization to first documented progression or deaths, planned to be assessed up to 37 months)

Posted results on ClinicalTrials.gov

Source: ClinicalTrials.gov results for NCT04816214 (opens in a new tab)· Licence: public-domain

First posted 30 Oct 2023 · Last update posted 5 Mar 2024 · Imported 26 Oct 2026 from ClinicalTrials.gov download 2026-10-25

Primary outcomes with a statistical analysis

No primary outcome with a statistical analysis is posted for this study.

Serious adverse events

Time frame: From first dose of treatment until 30 days after last dose of study treatment, assessed up to 39 weeks.

Participants with serious adverse events per group for GEOMETRY-E, as posted
Group	Affected	At risk
Run-in Part: Capmatinib + Osimertinib	2	6

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Results from company and journal sources

No editor-confirmed results are on record for this study.

Publications

No PubMed citation lists NCT04816214.

CT-VCA trial quality

About CT-VCA

Loading CT-VCA scores…

Data integrity

Compare what the registry, company releases, FDA documents and publications say about this study.

Drugs on HealthTrade

Capmatinib

Source

NCT04816214 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 25 Oct 2026

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Nothing on this page is medical or investment advice.